Skip to main content
. 2014 May 1;30(5):468–475. doi: 10.1089/aid.2013.0197

FIG. 3.

FIG. 3.

Clade-specific differences influence HLA-B*07:02 peptide binding and dictate epitope immunogenicity. (A) p17-RM9 B-clade and C-clade epitope binding half-life (stability); (B) lack of cross-reactivity in PBMCs from subject H034 (HLA-A*34:02/A*68:02, B*07:02/B*44:03, Cw04:01/Cw07:02) using IFN-γ ELISpot to peptide RM9 and variant RK9; (C) correlation between optimal epitope binding half-life and (D) affinity with recognition by IFN-γ ELISpot in HLA-B*07:02 individuals pooled for B-clade and C-clade infection.